The present invention provides variants of human β-Glucocerebrosidase protein.

A method for producing mono-ethylene glycol (MEG) from a wood-based raw material, and wherein method includes: i) providing a wood-based feedstock originating from the wood-based raw material and including wood chips, wherein at most 5 weight-% of the wood chips in the wood-based feedstock are overthick wood chips as specified by SCAN-CM 40:01, and subjecting the wood-based feedstock to at least one pretreatment to form a liquid fraction and a fraction including solid cellulose particles; ii) subjecting the fraction comprising solid cellulose particles to enzymatic hydrolysis to form a lignin fraction and a carbohydrate fraction; iii) subjecting the carbohydrate fraction to catalytical conversion to form a liquid composition of glycols; and iv) recovering mono-ethylene glycol from the liquid composition of glycols. Further is disclosed a corresponding arrangement and mono-ethylene glycol obtainable by the method.

A method for providing a low lactose milk-based product having GOS fiber is provided in which a milk substrate having lactose is treated with a transgalactosylating enzyme to provide GOS fiber and remaining lactose; deactivating the transgalactosylating enzyme; contacting the milk-based substrate having GOS fiber with a lactase to degrade the remaining lactose to provide the low lactose milk-based product having GOS fiber and deactivating the lactase. Also provided are enzymes and GOS fiber and lactose amounts and stability.

Disclosed are novel gene therapy constructs containing both HEXA and HEXB genes to treat GM2 gangliosidoses, including Sandhoff disease and Tay-Sach's disease. Also described are co-treatments using chaperone and anti-inflammatory agents to enhance the effects of gene therapy.

The present invention provides compositions and methods useful for treating cancers such as glioblastoma. SapC-DOPS was found to be synergistically effective at inducing cell death when administered in conjunction with rampamycin. SapC-DOPS/rapamycin combination therapy allows physicians to give lower doses of each drug and achieve better therapeutic efficacy. The compositions also allow for less toxicity and fewer off-target effects. Related methods and materials are also provided herein.

The present invention relates to xylanase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; compositions comprising the xylanase variants and methods of using the variants.

The present invention relates to compositions such as cleaning compositions comprising a mix of enzymes. The invention further relates to use of compositions comprising such enzymes in cleaning processes.

The present invention relates to a process of enzymatic degradation of an absorbent structure, the absorbent structure being suitable for providing an absorbent core of a hygiene article, wherein the process comprises the step of contacting the absorbent structure with a solution comprising enzymes; wherein the absorbent structure comprises a polysaccharide superabsorbent polymer, such as a cellulose-based or a starch-based superabsorbent polymer.

Disclosed herein are methods of treating a toxicity in a subject receiving recombinant viral vector, such as a recombinant adeno-associated viral AAV (rAAV) vector comprising co-administration of an antibiotic and a viral vector. In one embodiment, the antibiotic is a tetracycline or macrolide family member. Also provided herein are compositions comprising an antibiotic and a viral vector.

This invention relates to viral vectors for delivery of α-N-acetylglucosaminidase (NAGLU) to a subject. In some aspects the NAGLU sequence is optimized for expression in human cells. The invention further relates to methods of using the vector to increase secretion of NAGLU from a cell and for treatment and prevention of mucopolysaccharidosis IIIB.